| __timestamp | Cytokinetics, Incorporated | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44426000 | 5758000 |
| Thursday, January 1, 2015 | 46398000 | 8423000 |
| Friday, January 1, 2016 | 59897000 | 11986000 |
| Sunday, January 1, 2017 | 90296000 | 15215000 |
| Monday, January 1, 2018 | 89135000 | 15356000 |
| Tuesday, January 1, 2019 | 86125000 | 16660000 |
| Wednesday, January 1, 2020 | 96951000 | 52459000 |
| Friday, January 1, 2021 | 159938000 | 75061000 |
| Saturday, January 1, 2022 | 240813000 | 87221000 |
| Sunday, January 1, 2023 | 330123000 | 83779000 |
Cracking the code
In the dynamic world of biopharmaceuticals, understanding cost structures is crucial for investors and stakeholders. Over the past decade, Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Cytokinetics experienced a staggering increase of over 640%, peaking in 2023. This growth reflects their aggressive expansion and investment in research and development. In contrast, Supernus Pharmaceuticals saw a more modest rise of approximately 1,350% during the same period, indicating a steady yet cautious approach to scaling operations. Notably, 2020 marked a significant year for both companies, with Supernus's costs surging by 215% compared to the previous year, possibly due to increased production or strategic acquisitions. These insights highlight the contrasting strategies of two key players in the industry, offering valuable lessons in financial management and growth trajectories.
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Johnson & Johnson and Cytokinetics, Incorporated's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Cytokinetics, Incorporated and Xenon Pharmaceuticals Inc.'s Expenses
Cytokinetics, Incorporated vs PTC Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Mesoblast Limited
Cost of Revenue Trends: Cytokinetics, Incorporated vs Xencor, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses